NZ590922A - Piperidine derivatives as jak3 inhibitors - Google Patents
Piperidine derivatives as jak3 inhibitorsInfo
- Publication number
- NZ590922A NZ590922A NZ590922A NZ59092209A NZ590922A NZ 590922 A NZ590922 A NZ 590922A NZ 590922 A NZ590922 A NZ 590922A NZ 59092209 A NZ59092209 A NZ 59092209A NZ 590922 A NZ590922 A NZ 590922A
- Authority
- NZ
- New Zealand
- Prior art keywords
- formula
- compounds
- oxopropanenitrile
- methylpiperidin
- amino
- Prior art date
Links
- 150000003053 piperidines Chemical class 0.000 title abstract 2
- 229940123241 Janus kinase 3 inhibitor Drugs 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- DANQCJZYOJHPPW-NEPJUHHUSA-N 3-[(3r,4r)-4-methyl-3-[methyl([1,2,4]triazolo[1,5-a]pyrimidin-7-yl)amino]piperidin-1-yl]-3-oxopropanenitrile Chemical compound C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)C1=CC=NC2=NC=NN12 DANQCJZYOJHPPW-NEPJUHHUSA-N 0.000 abstract 1
- 102000015617 Janus Kinases Human genes 0.000 abstract 1
- 108010024121 Janus Kinases Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 230000004913 activation Effects 0.000 abstract 1
- 125000002619 bicyclic group Chemical group 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- 230000001575 pathological effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Transplantation (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US8570508P | 2008-08-01 | 2008-08-01 | |
| US9856208P | 2008-09-19 | 2008-09-19 | |
| PCT/US2009/052449 WO2010014930A2 (en) | 2008-08-01 | 2009-07-31 | Therapeutic agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ590922A true NZ590922A (en) | 2012-09-28 |
Family
ID=41170025
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ590922A NZ590922A (en) | 2008-08-01 | 2009-07-31 | Piperidine derivatives as jak3 inhibitors |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20110165183A1 (enExample) |
| EP (1) | EP2324020A2 (enExample) |
| JP (1) | JP2011529918A (enExample) |
| KR (1) | KR20110050654A (enExample) |
| CN (1) | CN102171211A (enExample) |
| AU (1) | AU2009276420A1 (enExample) |
| BR (1) | BRPI0916931A2 (enExample) |
| CA (1) | CA2732628A1 (enExample) |
| IL (1) | IL210990A0 (enExample) |
| MX (1) | MX2011001259A (enExample) |
| NZ (1) | NZ590922A (enExample) |
| RU (1) | RU2011105768A (enExample) |
| WO (1) | WO2010014930A2 (enExample) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW201107330A (en) | 2009-07-31 | 2011-03-01 | Biocryst Pharm Inc | Heterocyclic compounds as janus kinase inhibitors |
| MX2012013824A (es) * | 2010-05-28 | 2013-03-12 | Biocryst Pharm Inc | Compuestos heterociclicos como inhibidores de cinasa janus. |
| AU2012255792A1 (en) * | 2011-05-17 | 2013-11-07 | Principia Biopharma Inc. | Azaindole derivatives as tyrosine kinase inhibitors |
| EA201491667A1 (ru) | 2012-03-13 | 2015-03-31 | Басф Се | Фунгицидные соединения пиримидина |
| KR102203990B1 (ko) | 2012-09-10 | 2021-01-18 | 프린시피아 바이오파마, 인코퍼레이티드 | 키나제 저해제로서의 피라졸로피리미딘 화합물 |
| CA2890201A1 (en) * | 2012-11-20 | 2014-05-30 | Glaxosmithkline Llc | Novel compounds |
| EP2935216B1 (en) * | 2012-12-17 | 2018-06-27 | Sun Pharmaceutical Industries Limited | Process for the preparation of tofacitinib and intermediates thereof |
| EP2938616A4 (en) | 2012-12-28 | 2016-06-15 | Glenmark Pharmaceuticals Ltd | PROCESSING METHOD FOR THE PRODUCTION OF TOFACITINIB AND INTERMEDIATE PRODUCTS THEREOF |
| CN105722833A (zh) | 2013-09-16 | 2016-06-29 | 巴斯夫欧洲公司 | 杀真菌的嘧啶化合物 |
| WO2015036059A1 (en) | 2013-09-16 | 2015-03-19 | Basf Se | Fungicidal pyrimidine compounds |
| CA2925211A1 (en) * | 2013-09-27 | 2015-04-02 | Nimbus Iris, Inc. | Irak inhibitors and uses thereof |
| HUE042911T2 (hu) * | 2013-12-09 | 2019-07-29 | Unichem Lab Ltd | Javított eljárás a (3R,4R)-(1-benzil-4-metil-piperidin-3-il)-metilamin elõállítására |
| ES2841248T3 (es) | 2014-02-21 | 2021-07-07 | Principia Biopharma Inc | Sales y forma sólida de un inhibidor de BTK |
| CN104860950A (zh) * | 2014-02-24 | 2015-08-26 | 重庆医药工业研究院有限责任公司 | 一种制备4-氯吡咯[2,3-d]并嘧啶的方法 |
| CN104059016A (zh) * | 2014-06-20 | 2014-09-24 | 湖南天地恒一制药有限公司 | 制备托法替布的中间体及所述中间体的制备方法 |
| KR101710127B1 (ko) * | 2014-08-29 | 2017-02-27 | 한화제약주식회사 | 야누스인산화효소 억제제로서의 치환된 N-(피롤리딘-3-일)-7H-피롤로[2,3-d]피리미딘-4-아민 |
| EP3233103B1 (en) | 2014-12-18 | 2020-10-14 | Principia Biopharma Inc. | Treatment of pemphigus |
| CN105732637B (zh) * | 2014-12-30 | 2020-04-21 | 广东东阳光药业有限公司 | 杂芳化合物及其在药物中的应用 |
| EP3078665A1 (en) | 2015-04-10 | 2016-10-12 | OLON S.p.A. | Efficient method for the preparation of tofacitinib citrate |
| CA2990145A1 (en) * | 2015-06-22 | 2016-12-29 | Ono Pharmaceutical Co., Ltd. | Brk inhibitory compound |
| MA42242A (fr) | 2015-06-24 | 2018-05-02 | Principia Biopharma Inc | Inhibiteurs de la tyrosine kinase |
| WO2017004134A1 (en) * | 2015-06-29 | 2017-01-05 | Nimbus Iris, Inc. | Irak inhibitors and uses thereof |
| CN105622616A (zh) * | 2016-02-25 | 2016-06-01 | 上海雅本化学有限公司 | 一种4-氯吡咯并嘧啶的制备方法 |
| KR102391693B1 (ko) | 2016-06-29 | 2022-04-29 | 프린시피아 바이오파마, 인코퍼레이티드 | 2-[3-[4-아미노-3-(2-플루오로-4-페녹시-페닐)피라졸로[3,4-d]피리미딘-1-일]피페리딘-1-카르보닐]-4-메틸-4-[4-(옥세탄-3-일)피페라진-1-일]펜트-2-엔니트릴의 변형 방출 제제 |
| GB201617758D0 (en) | 2016-10-20 | 2016-12-07 | Almac Discovery Limited | Pharmaceutical compounds |
| WO2019201194A1 (zh) * | 2018-04-16 | 2019-10-24 | 深圳市塔吉瑞生物医药有限公司 | 取代的吡咯并三嗪类化合物及其药物组合物及其用途 |
| EP4045051A1 (en) | 2019-10-14 | 2022-08-24 | Principia Biopharma Inc. | Methods for treating immune thrombocytopenia by administering (r)-2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile |
| WO2021150723A1 (en) | 2020-01-22 | 2021-07-29 | Principia Biopharma Inc. | Crystalline forms of 2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)-1h-pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile |
| CN116768908B (zh) * | 2022-03-10 | 2025-11-18 | 石家庄迪斯凯威医药科技有限公司 | 一种含n多环化合物及其制备方法与用途 |
| CN117164519A (zh) * | 2023-08-18 | 2023-12-05 | 杭州小蓓医药科技有限公司 | 一种l-肌肽的合成方法 |
| CN117534603A (zh) * | 2023-11-10 | 2024-02-09 | 江苏海悦康医药科技有限公司 | 一种托法替布中间体的制备方法 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CZ20004727A3 (cs) * | 1998-06-19 | 2002-03-13 | Pfizer Products Inc. | Deriváty pyrrolo[2,3-d] pyrimidinu |
| AU777911B2 (en) * | 1999-12-10 | 2004-11-04 | Pfizer Products Inc. | Pyrrolo(2,3-d)pyrimidine compounds |
| UA74370C2 (uk) * | 2000-06-26 | 2005-12-15 | Пфайзер Продактс Інк. | Піроло(2,3-d)піримідинові сполуки як імуносупресори |
| US7301023B2 (en) * | 2001-05-31 | 2007-11-27 | Pfizer Inc. | Chiral salt resolution |
| BR0316487A (pt) * | 2002-11-26 | 2005-10-11 | Pfizer Prod Inc | Método todo de tratamento da rejeição de transplantes |
| EP1620437B1 (en) * | 2003-04-29 | 2009-06-17 | Pfizer Limited | 5,7-diaminopyrazolo¬4,3-d pyrimidines useful in the traetment of hypertension |
| BRPI0416909A (pt) * | 2003-11-25 | 2007-01-16 | Pfizer Prod Inc | método de tratamento de aterosclerose |
| AR054416A1 (es) * | 2004-12-22 | 2007-06-27 | Incyte Corp | Pirrolo [2,3-b]piridin-4-il-aminas y pirrolo [2,3-b]pirimidin-4-il-aminas como inhibidores de las quinasas janus. composiciones farmaceuticas. |
| CA2615291A1 (en) * | 2005-07-14 | 2007-01-18 | Astellas Pharma Inc. | Heterocyclic janus kinase 3 inhibitors |
| NL2000291C2 (nl) * | 2005-11-10 | 2009-02-17 | Pfizer Prod Inc | 1-(1-(2-ethoxyethyl)-3-ethyl-7-(4-methylpyridin-2-ylamino)-1H- pyrazool(4,3-d)pyrimidine-5-yl)piperidine-4-carbonzuur en zouten daarvan. |
| TW201111385A (en) * | 2009-08-27 | 2011-04-01 | Biocryst Pharm Inc | Heterocyclic compounds as janus kinase inhibitors |
| CN103442568A (zh) * | 2010-10-08 | 2013-12-11 | Abbvie公司 | 呋喃并[3,2-d]嘧啶化合物 |
-
2009
- 2009-07-31 BR BRPI0916931A patent/BRPI0916931A2/pt not_active IP Right Cessation
- 2009-07-31 CA CA2732628A patent/CA2732628A1/en not_active Abandoned
- 2009-07-31 WO PCT/US2009/052449 patent/WO2010014930A2/en not_active Ceased
- 2009-07-31 NZ NZ590922A patent/NZ590922A/xx not_active IP Right Cessation
- 2009-07-31 US US13/057,100 patent/US20110165183A1/en not_active Abandoned
- 2009-07-31 JP JP2011521361A patent/JP2011529918A/ja active Pending
- 2009-07-31 EP EP09791064A patent/EP2324020A2/en not_active Withdrawn
- 2009-07-31 MX MX2011001259A patent/MX2011001259A/es unknown
- 2009-07-31 RU RU2011105768/04A patent/RU2011105768A/ru not_active Application Discontinuation
- 2009-07-31 KR KR1020117004724A patent/KR20110050654A/ko not_active Withdrawn
- 2009-07-31 CN CN2009801396041A patent/CN102171211A/zh active Pending
- 2009-07-31 AU AU2009276420A patent/AU2009276420A1/en not_active Abandoned
-
2011
- 2011-02-01 IL IL210990A patent/IL210990A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20110165183A1 (en) | 2011-07-07 |
| JP2011529918A (ja) | 2011-12-15 |
| WO2010014930A3 (en) | 2010-07-29 |
| CA2732628A1 (en) | 2010-02-04 |
| CN102171211A (zh) | 2011-08-31 |
| RU2011105768A (ru) | 2012-09-10 |
| EP2324020A2 (en) | 2011-05-25 |
| KR20110050654A (ko) | 2011-05-16 |
| AU2009276420A1 (en) | 2010-02-04 |
| BRPI0916931A2 (pt) | 2015-11-24 |
| IL210990A0 (en) | 2011-04-28 |
| WO2010014930A2 (en) | 2010-02-04 |
| MX2011001259A (es) | 2011-03-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ590922A (en) | Piperidine derivatives as jak3 inhibitors | |
| MY146474A (en) | Imidazo[1,2-b]pyridazine and pyrazolo[1,5-a]pyrimidine derivatives and their use as protein kinase inhibitors | |
| NZ623922A (en) | Novel tricyclic compounds | |
| ZA200802998B (en) | Use of pyrazolo [1,5-a] pyrimidine derivatives for inhibiting protein kinases methods for inhibiting protein kinases | |
| CN103339134A (zh) | 三环吡咯并衍生物、它们的制备方法和它们作为激酶抑制剂的应用 | |
| CA2749483C (en) | Processes for preparing jak inhibitors and related intermediate compounds | |
| WO2007120752A3 (en) | 4, 5-dihydro- [1, 2, 4] triazolo [4, 3-f] pteridines as protein kinase plk1 inhibitors for the treatment of proliferative disorders | |
| MX2010009458A (es) | Derivados biciclicos heterociclicos o espirobiciclicos heterociclicos enlazados, de pirazolo[1,5-a]pirimidinas, procedimientos para su preparacion y usos de los mismos. | |
| MX2007006497A (es) | Nuevos derivados de pirrolo [3,2-d] pirimidin-4-ona y su uso en terapia. | |
| SG196855A1 (en) | Substituted pyrazolo[1,5-a]pyrimidine compounds as trk kinase inhibitors | |
| WO2009151997A8 (en) | Process for producing bicycloaniline derivatives | |
| NZ601687A (en) | Azaindoles useful as inhibitors of janus kinases | |
| MX337817B (es) | Pirazolo [1,5-a] pirimidinas de utilidad como inhibidores de proteina quinasas. | |
| WO2008070313A3 (en) | 3-(dihydro-1h-pyrazolo [4,3-d] pyrimidin-5-yl)-4-propoxybenzenesulfonamide derivatives and methods of use | |
| US10421765B2 (en) | Tetrahydropyrido[4,3-d]pyrimidine inhibitors of ATR kinase | |
| WO2007061764A3 (en) | Tricyclic compounds useful as inhibitors of kinases | |
| KR20140015151A (ko) | 신규한 트리사이클릭 화합물 | |
| MX2012001420A (es) | Derivados de pirrolo[1,2-b]piridazina como inhibidores de cinasa janus. | |
| MY152386A (en) | Substituted 6a,7,8,9-tetrahydropyrido[3,2-e] pyrrolo[1,2-a]pyrazin-6(5h)-ones | |
| WO2004009597A3 (en) | Pyrazolopyrimidines as protein kinase inhibitors | |
| FR3052452A1 (enExample) | ||
| MX2010006748A (es) | Pirazolo[1,5-a]pirimidinas utiles como inhibidores de jak2. | |
| TW201402577A (zh) | 包含經取代嗎福啉之新穎２，３－二氫－１Ｈ－咪唑并｛１，２－ａ｝嘧啶－５－酮及１，２，３，４－四氫嘧啶并｛１，２－ａ｝嘧啶－６－酮衍生物，其製備及其醫療用途 | |
| WO2007032936A3 (en) | Azafused cyclin dependent kinase inhibitors | |
| Musumeci et al. | Pyrrolo [2, 3-d] pyrimidines as kinase inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| LAPS | Patent lapsed |